Skip to content
Homepage
Author:
Vanotech Ltd
Posted Date:
May 15, 2026
Kanghong Pharmaceutical and Vanotech Announce Positive Phase 2b Results for KH607 in Major Depressive Disorder
Vanotech Ltd
May 15, 2026
Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations
Vanotech Ltd
May 13, 2026
